Drugs / DVC LVS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01150695 | Sep 2010 → Jan 2012 | tularemia | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DVC LVS | “Study Group A will include 110 volunteers who will be vaccinated with a single dose of the DVC LVS product in one arm and normal saline (NS) control in the other arm on Day 0.” NCT01150695 ↗1“About half of the volunteers will be placed in the DVC-LVS vaccine group and half of volunteers will be placed in the USAMRIID-LVS vaccine group.” NCT01150695 ↗ |
| Modality | Vaccine | “Francisella tularensis live vaccine strain (LVS) vaccine” NCT01150695 ↗ |
| Route | Other | “Both vaccines will be administered by scarification.” NCT01150695 ↗ |